Best Growth Stocks to Buy for June 15th

Zacks highlighted DaVita, Five Below and Pitney Bowes as Rank #1 stocks, with current-year earnings estimates rising 6.4%, 8.1% and 11% over the last 60 days, respectively. Each name also screens attractively on PEG versus industry, with DaVita at 0.65, Five Below at 1.09 and Pitney Bowes at 0.75. The article is fundamentally positive but largely a stock-screening piece, so near-term market impact should be limited.

Analysis

The common factor across the three names is not “growth” per se, but rising estimate confidence in businesses the market usually values as ex-growth/low-quality. That matters because estimate revisions tend to matter more than headline multiples in the next 1-2 quarters: if revisions continue, these names can re-rate even without major multiple expansion. The setup is strongest where valuation is still below the sector median, because the market has room to buy into the upgrade cycle rather than simply paying up for a crowded momentum trade.

The second-order effect is most interesting in consumer and logistics. A name like FIVE benefits if household spending remains resilient, but the real upside comes from assortment leverage and better traffic conversion, which can pull share from weaker discretionary chains with less pricing power. For PBI, the risk is that improving earnings estimates may be masking a slow-burn structurally challenged core; if the market is rewarding cost-cutting or mix improvement rather than durable demand, the upside can reverse quickly once the cadence of beats slows.

DVA is the most defensible quality/value combination here because the business has recurring demand and the market tends to underwrite it as a stable cash-flow compounder rather than a growth asset. That creates a path for multiple expansion if management can show that earnings revisions are not just accounting-driven but supported by operating leverage and payer mix stability. The contrarian read: the crowd may be overpaying for estimate momentum in FIVE and underestimating how quickly PBI can become a value trap if the revision cycle peaks.

Near term, the cleanest catalyst window is the next 1-2 earnings prints, when upward estimate drift can either be validated or reset. If revisions keep climbing into the print, these names can outperform simply because positioning is usually not crowded in lower-profile Zacks #1 stocks; if the market starts questioning the durability of the upgrade path, the downside can be sharp because these are not priced for perfection but are priced for improvement.

Key Decisions for Investors

• Long DVA into the next earnings cycle (4-8 weeks) as a lower-volatility relative value long; target 8-12% upside if revisions keep trending higher, with downside likely limited to low-single digits absent a broader defensive selloff.
• Long FIVE only on pullbacks over the next 2-6 weeks; treat it as a momentum-plus-consumer-demand trade with a tighter stop, since the upside is meaningful if traffic holds but multiple compression could erase gains quickly if comps soften.
• Use PBI as a tactical long, not a core hold; consider a 1-2 month position for mean reversion, but take profits aggressively on any gap-up tied to estimates because the market may be paying for cost-cutting rather than durable growth.
• Pair trade: long DVA / short a basket of lower-quality healthcare laggards over the next quarter; the goal is to own recurring-demand resilience while fading businesses where estimate revisions are less credible.
• For risk control, reduce exposure if the next consensus revision cycle stalls for any of the three names; the trade thesis is revision momentum, so flattening estimates is the clearest signal to exit.